21-FEB-2025 6:10

MMYEL ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1803-MM, Maintenance, Len vs Len/Dara 1 N 0 Screening 1420 1448 269 140 63 0 0 08/13/2019 328 128
            1448 269 140 63 0 0      
 
    2 Y 1 Lenalidomide   667 123 64 30 9 2 08/13/2019    
        2 Lenalidomide + Daratumumab   655 122 59 28 6 1      
            1322 245 123 58 15 3      
 
    3 Y 3 Stop vs Continue Treatment   235 69 36 16 5 2 08/13/2019    
            235 69 36 16 5 2      
 
  S2005-WM, Prev. Untreated, I/R +/- Venetoclax 1 Y 1 I+R 92 6 6 4 2 0 0 01/05/2022 75 22
        2 I+R+Venetoclax   1 0 0 0 0 0      
        3 V+R   5 5 2 1 0 0      
            12 11 6 3 0 0      
 
  S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D 1 Y 1 VRD-R 510 22 17 11 6 2 1 10/12/2023 218 83
        2 DRD-R   22 17 10 5 1 0      
        3 DRD-DR   20 15 9 3 1 0      
            64 49 30 14 4 1      
 
  S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 1 Y 0 Induction 338 9 9 7 4 1 0 07/01/2024 125 41
            9 9 7 4 1 0      
 
    2 Y 1 Dara-VCD   1 1 1 0 0 0 07/01/2024    
        2 Melphalan + ASCT   2 2 2 2 1 0      
            3 3 3 2 1 0      
 
Yes EAA181-Myel, Newly Dx, DRd=>DRd+/-Btz=>DR (EQUATE) 0 E Total Registrations   51 7 5 1 1 0 05/27/2021 205 81
            51 7 5 1 1 0      
 
    1 E Total Registrations   37 4 2 0 0 0 05/27/2021    
            37 4 2 0 0 0      
 
    2 E Total Registrations   29 15 7 3 0 0 05/27/2021    
            29 15 7 3 0 0      
 
No EAA173-MYEL, SMM, Rd +/- Daratumumab 0 E Total Registrations   75 17 4 1 0 0 01/08/2020 233 99
            75 17 4 1 0 0      
 
    1 E Total Registrations   37 11 5 2 0 0 01/08/2020    
            37 11 5 2 0 0      
 

21-FEB-2025 6:10

MMYEL Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
S2005 WM, Prev. Untreated, I/R +/- Venetoclax 2 Crossover 24-Jun-21 75 22
S2213 AL Amyloidosis, Newly Dx, Dara-VCD v ASCT 3 Maintenance 01-Dec-23 125 41